125.00
price up icon0.35%   0.44
pre-market  Pre-market:  124.01   -0.99   -0.79%
loading
Neurocrine Biosciences Inc stock is traded at $125.00, with a volume of 1.26M. It is up +0.35% in the last 24 hours and up +13.97% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$124.56
Open:
$124.86
24h Volume:
1.26M
Relative Volume:
0.85
Market Cap:
$12.37B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
42.37
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+1.92%
1M Performance:
+13.97%
6M Performance:
-0.35%
1Y Performance:
-10.66%
1-Day Range:
Value
$123.41
$126.33
1-Week Range:
Value
$121.42
$126.33
52-Week Range:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
125.00 12.14B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.05 50.54B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
170.30 74.02B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.86 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.97 45.82B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.19 20.31B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
Jun 03, 2025

(NBIX) Technical Data - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nxera earns $15 million as Neurocrine advances schizophrenia drug - The Pharma Letter

Jun 03, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Projects Strong Ingrezza Sales For 2025 - Finimize

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewswire Inc.

Jun 02, 2025
pulisher
Jun 02, 2025

Analyst Expectations For Neurocrine Biosciences's Future - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Announces Phase 4 KINECT-PRO Data - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

[Latest] USA Tardive Dyskinesia Treatment Market: New Drugs, - openPR.com

Jun 02, 2025
pulisher
Jun 02, 2025

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia - PR Newswire

Jun 02, 2025
pulisher
Jun 01, 2025

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia - Quantisnow

Jun 01, 2025
pulisher
May 30, 2025

Huntington's Disease Society hosts Team Hope Walk in Tulsa Saturday - KTUL

May 30, 2025
pulisher
May 30, 2025

Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX) - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - MSN

May 30, 2025
pulisher
May 30, 2025

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III - insights.citeline.com

May 30, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com

May 29, 2025
pulisher
May 29, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News

May 29, 2025
pulisher
May 29, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - The Malaysian Reserve

May 29, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 28, 2025

First-in-Class Schizophrenia Treatment Achieves Major Clinical Milestone: Phase 2 Success Signals New Era - Stock Titan

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - PR Newswire

May 16, 2025
pulisher
May 15, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan

May 15, 2025
pulisher
May 14, 2025

Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal

May 14, 2025
pulisher
May 14, 2025

New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan

May 14, 2025
pulisher
May 13, 2025

15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com

May 13, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.66
price down icon 0.54%
drug_manufacturers_specialty_generic HCM
$14.70
price up icon 8.09%
$8.71
price up icon 0.23%
$324.20
price down icon 0.39%
$17.19
price down icon 0.41%
Cap:     |  Volume (24h):